Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
New research reveals how repurposing existing drugs could offer faster, safer therapeutic options for Alzheimer's disease treatment and prevention.
By Peptide Association Research Team
New research reveals how existing medications could be repurposed for Alzheimer's treatment, offering hope beyond traditional therapies with known safety profiles.
By Peptide Association Research Team
New research reveals how existing drugs like metformin and GLP-1 agonists may offer alternative approaches to Alzheimer's treatment through repurposing strategies.
By Peptide Association Research Team
New research reveals how existing medications could be repurposed for Alzheimer's disease treatment, offering hope beyond current limited therapies.
By Peptide Association Research Team
New research explores repurposing existing drugs for Alzheimer's treatment, highlighting mitochondrial-targeted therapies and multi-target approaches.
By Peptide Association Research Team